RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Auris Medical Holding - Stock

Auris Medical Holding P/S 2024

Auris Medical Holding P/S

0

Ticker

EARS

ISIN

BMG070252017

WKN

A2PJN3

As of Jun 20, 2024, Auris Medical Holding's P/S ratio stood at 0, a 0% change from the 0 P/S ratio recorded in the previous year.

The Auris Medical Holding P/S history

Auris Medical Holding Aktienanalyse

What does Auris Medical Holding do?

Auris Medical Holding Ltd is a biopharmaceutical company that was founded in 2013 and is headquartered in Zug, Switzerland. The company specializes in the development and marketing of products in the field of hearing and hearing impairment. The history of Auris Medical Holding Ltd began with the founding of the company by Thomas Meyer and Daniel J. Salomon, both of whom had extensive experience in the biotech industry and investment banking. The company went public on the NASDAQ stock exchange in 2014 and has since expanded its business steadily. Auris Medical's business model is based on the development of innovative therapies and medications for disorders in the ENT field. The company focuses on the needs of patients with hearing and hearing impairment due to neurosensory disorders. In this area, there are currently only a few approved therapies, which represents a significant unmet medical need. Auris Medical divides its activities into two divisions: the development of clinical therapies and the marketing of products for the treatment of tinnitus and hearing loss. In the field of clinical therapies, the company specializes in the development of medications for restoring hearing. Among other things, Auris Medical is working on the development of AM-111, a treatment for acute inner ear damage that can lead to sudden hearing loss. Auris Medical also operates its own distribution chain, which offers products for the treatment of tinnitus and hearing loss. These products are marketed under the name Tinnitool and include devices for relieving tinnitus and hearing loss. The company also offers audiology services to perform individual audiological evaluations. Overall, Auris Medical Holding Ltd has a wide range of products aimed at the needs of patients with hearing and hearing impairment. From medications to symptom relief products to diagnostic services, the company is able to address various aspects of the health issue. As an innovative company, Auris Medical Holding Ltd invests heavily in research and development of new therapies and medications. The company collaborates with leading experts in the field of hearing and hearing impairment to improve its technologies and products. Additionally, the company aims to expand into further regions to reach a broader patient base. In summary, Auris Medical Holding Ltd is an emerging company in the field of hearing and hearing impairment. With a wide product portfolio tailored to the needs of patients, the company invests in research and development to develop new therapies and medications. Through its innovation and strong partnerships in the field of hearing and hearing impairment, the company plans to establish itself as a leading company in this field. Auris Medical Holding ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Auris Medical Holding's P/S Ratio

Auris Medical Holding's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Auris Medical Holding's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Auris Medical Holding's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Auris Medical Holding’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Auris Medical Holding Stock

What is the price-to-earnings ratio of Auris Medical Holding?

The price-earnings ratio of Auris Medical Holding is currently 0.

How has the price-earnings ratio of Auris Medical Holding changed compared to last year?

The price-to-earnings ratio of Auris Medical Holding has increased by 0% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Auris Medical Holding high compared to other companies?

Yes, the price-to-earnings ratio of Auris Medical Holding is high compared to other companies.

How does an increase in the price-earnings ratio of Auris Medical Holding affect the company?

An increase in the price-earnings ratio of Auris Medical Holding would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Auris Medical Holding affect the company?

A decrease in the price-earnings ratio of Auris Medical Holding would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Auris Medical Holding?

Some factors that influence the price-earnings ratio of Auris Medical Holding are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Auris Medical Holding pay?

Over the past 12 months, Auris Medical Holding paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Auris Medical Holding is expected to pay a dividend of 0 CHF.

What is the dividend yield of Auris Medical Holding?

The current dividend yield of Auris Medical Holding is .

When does Auris Medical Holding pay dividends?

Auris Medical Holding pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Auris Medical Holding?

Auris Medical Holding paid dividends every year for the past 0 years.

What is the dividend of Auris Medical Holding?

For the upcoming 12 months, dividends amounting to 0 CHF are expected. This corresponds to a dividend yield of 0 %.

In which sector is Auris Medical Holding located?

Auris Medical Holding is assigned to the 'Health' sector.

Wann musste ich die Aktien von Auris Medical Holding kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Auris Medical Holding from 6/20/2024 amounting to 0 CHF, you needed to have the stock in your portfolio before the ex-date on 6/20/2024.

When did Auris Medical Holding pay the last dividend?

The last dividend was paid out on 6/20/2024.

What was the dividend of Auris Medical Holding in the year 2023?

In the year 2023, Auris Medical Holding distributed 0 CHF as dividends.

In which currency does Auris Medical Holding pay out the dividend?

The dividends of Auris Medical Holding are distributed in CHF.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Auris Medical Holding

Our stock analysis for Auris Medical Holding Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Auris Medical Holding Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.